Abstract:Clustered regularly interspersed short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology has revolutionized the field of gene therapy as it has enabled precise genome editing with unprecedented accuracy and efficiency, paving the way for clinical applications to treat otherwise incurable genetic disorders. Typically, precise genome editing requires the delivery of multiple components to the target cells that, depending on the editing platform used, may include messenger RNA (mRNA), protein complexes, and DNA fragments. For clinical purposes, these have to be efficiently delivered into transplantable cells, such as primary T lymphocytes or hematopoietic stem and progenitor cells that are typically sensitive to exogenous substances. This challenge has limited the broad applicability of precise gene therapy applications to those strategies for which efficient delivery methods are available. Electroporation-based methodologies have been generally applied for gene editing applications, but procedure-associated toxicity has represented a major burden. With the advent of novel and less disruptive methodologies to deliver genetic cargo to transplantable cells, it is now possible to safely and efficiently deliver multiple components for precise genome editing, thus expanding the applicability of these strategies. In this review, we describe the different delivery systems available for genome editing components, including viral and non-viral systems, highlighting their advantages, limitations, and recent clinical applications. Recent improvements to these delivery methods to achieve cell specificity represent a critical development that may enable in vivo targeting in the future and will certainly play a pivotal role in the gene therapy field.

When Mrna Meets Gene Editing

Nanobiomaterial Vectors for Improving Gene Editing and Gene Therapy

Novel Vectors and Administrations for Mrna Delivery

Engineered mRNA Delivery Systems for Biomedical Applications

Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets

Intracellular Delivery of mRNA for Cell-Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles

Nanoscale Platforms for Messenger RNA Delivery

Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities

Mrna Nanodelivery Systems: Targeting Strategies and Administration Routes

Viral and nonviral nanocarriers for in vivo CRISPR-based gene editing

Intelligent nanotherapeutic strategies for the delivery of CRISPR system

Nano-vectors for CRISPR/Cas9-mediated genome editing

Non-viral strategies for delivering genome editing enzymes

Engineered materials for in vivo delivery of genome-editing machinery

Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy

Efficient Delivery of Mrna Using Crosslinked Nucleic Acid Nanogel As a Carrier

Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery

Non-viral Nanocarriers for CRISPR-Cas9 Gene Editing System Delivery

Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics

Delivery technologies for genome editing

Delivery of CRISPR/Cas9 by novel strategies for gene therapy.